Drug Type CAR-NK |
Synonyms CYT 503, CYT-503 |
Target |
Mechanism GPC3 modulators(Glypican-3 modulators), Immunologic cytotoxicity, Natural killer cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Preclinical | US | Cytovia Therapeutics, Inc.Startup | 19 Feb 2021 |
Hepatocellular Carcinoma | Preclinical | US | 12 Feb 2020 |